BERLIN, June 5 /PRNewswire-USNewswire/ -- In an effort to foster global biomedical research that will ultimately lead to new and improved treatments for patients with blood diseases, the American Society of Hematology (ASH) and the European Hematology Association (EHA) have collaborated to create the Translational Research Training in Hematology (TRTH) program. This program will provide promising translational investigators an opportunity to undertake intensive training in the causes, diagnosis, and experimental treatment of hematologic disorders from some of the most recognized names in the field.
"The next generation of translational researchers will need to understand how to direct research in both the European and U.S. systems," said TRTH co-director and past ASH president Kenneth Kaushansky, MD. "This unique cross-cultural program provides participants with ongoing mentoring, a supportive peer network, and a depth of knowledge and experience that will help position them as global leaders in the field of translational research."
The inaugural TRTH will bring 20 early-career scientists to Marbella, Spain, during the week of March 20-26, 2010. Practical sessions will focus on career development, featuring career retrospectives from leaders in the field of hematology and panel discussions on grant preparation and funding sources; while instructional sessions will prepare participants to conduct hypothesis-driven research, design phase I and II clinical trials, and utilize animal models, diagnostics, and biomarkers in translational research.
"This rigorous one-week training course will allow participants to work with faculty in small groups to review and refine their individual research proposals," said program co-director and EHA president Willem Fibbe, MD. "The goal is for each of them to leave here with a competitive proposal so that they are ready to take the next step in applying for funding. We look forward to hearing about their progress when the group reconvenes at the ASH and EHA annual meetings."
Medical trainees, biomedical trainees, and pharmaceutical doctorate trainees generally within 12 years of MD graduation or with less than eight years of post-doctoral experience are encouraged to apply; trainees must be an EHA or ASH member. Applications will be available on the ASH and EHA Web sites starting June 15, 2009.
Reporters who wish to learn more about the ASH-EHA Translational Research Training in Hematology program may contact Patrick C. Irelan at 202-776-0544 or firstname.lastname@example.org.
The American Society of Hematology (www.hematology.org) is the world's largest professional society concerned with the causes and treatment of blood disorders. Its mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology. In September, ASH launched Blood: The Vital Connection (www.bloodthevitalconnection.org), a credible online resource addressing bleeding and clotting disorders, anemia, and cancer. It provides hematologist-approved information about these common blood conditions including risk factors, preventive measures, and treatment options.
The European Hematology Association (www.ehaweb.org) aims to promote excellence in clinical practice, research, and education in European hematology. Today, EHA - with over 3,000 active members from 95 countries - is a consolidated organization that pursues a large and growing number of projects and programs.
|SOURCE American Society of Hematology|
Copyright©2009 PR Newswire.
All rights reserved